Acute myeloid leukemia

Delta-Fly Pharma Inc.: Update on the R&D status of DFP-10917 and DFP-14927, a novel PEG Drug Conjugate, in the patients with R/R AML

Retrieved on: 
Friday, January 5, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Neoplasm, PEGylation, PEG, Cancer, Patent, VTX, Patient, Acute myeloid leukemia, ADC, AML, Pharmaceutical industry

Following the previous information on June 30th in 2023, we are excited to share our latest development status.

Key Points: 
  • Following the previous information on June 30th in 2023, we are excited to share our latest development status.
  • A Phase III study of DFP-10917 in patients with recurrent or refractory acute myeloid leukemia (R/R AML) at multicenter in the US is undergoing of the interim analysis.
  • A Phase I/II study of DFP-10917 in the combination with Venetoclax (VTX) in patients with R/R AML in the U.S. is in preparation.
  • Please find out the innovation for the miserable cancer patients by Delta-Fly Pharma Inc. and contact with us.

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Retrieved on: 
Thursday, January 4, 2024
CBFA2T3, Lung cancer, ESMO, Division, Woman, IND, Ovarian cancer, Drug discovery, PD-1, PROC, Spacecraft, Neutropenia, SAN, Gynecologic Oncology (journal), RAM, Endometrial cancer, Q&A, STRO, University, ASH, Bevacizumab, Patient, Phenotype, Acute myeloid leukemia, Safety, Webcast, ADC, NSCLC, AML, Birth control

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), is hosting an investor webcast today highlighting the significant potential of luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC. The presentation will include an overview of the clinical data supporting luvelta’s broad opportunity to address the unmet need in several FolRα-expressing cancers, including platinum-resistant ovarian cancer (PROC), endometrial cancer, CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) acute myeloid leukemia (AML), and non-small cell lung cancer (NSCLC).

Key Points: 
  • “Luvelta has been studied in over 180 patients to-date, and has demonstrated both promising clinical activity and a tolerable safety profile.
  • We are optimistic about its potential to change the cancer treatment landscape,” said Bill Newell, Sutro’s Chief Executive Officer.
  • “This includes the potential to be the first ADC to treat ovarian cancer patients with low to medium FolRα expression, which could double the current eligible patient population relative to the FolRα-targeting ADC on the market.
  • Sutro management and Dr. Monk will participate in a Q&A session at the end of the presentation.

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

Retrieved on: 
Thursday, January 4, 2024
Patient, Food, Acute leukemia, Neoplasm, Immunotherapy, PRAME, Amgen, IND, Collection, MRD, TCR, FDA, Antigen, HLA, Trial of the century, Society, Therapy, MDS, Infrared spectroscopy correlation table, Cancer, Disclosure, ASH, Annual general meeting, HCT, MAGE-C2, Syndrome, Poster, Safety, ALL, Acute myeloid leukemia, C2, AML, MAGE-A1, Food and Drug Administration, HPV16, SITC, Pharmaceutical industry

WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced its 2024 clinical pipeline plans and highlighted recent corporate achievements.

Key Points: 
  • Additionally, we submitted INDs for two additional TCRs in December and the 30-day review period with the FDA is ongoing.
  • Plans to complete Phase 1 dosing and report clinical and translational data in 2024, and two-year relapse data in 2025.
  • Initiated Phase 1 solid tumor clinical study and expects to dose the first patient in the first quarter of 2024.
  • Plans to continue to build ImmunoBank with additional IND filings throughout 2024.

Meet the St. Baldrick's Foundation 2024 Ambassadors

Retrieved on: 
Wednesday, January 3, 2024
Immunosuppression, MRI, Neoplasm, Swimming, Acute lymphoblastic leukemia, APL, Research, St. Baldrick's Foundation, Ambassador, Jack Sparrow, Clinical trial, Cancer, Juju, Acute promyelocytic leukemia, LOS, Dance, Acute myeloid leukemia, Diagnosis, ALL, Ewing sarcoma, AML, San Diego State University, Radiation, Child

LOS ANGELES, Jan. 3, 2024 /PRNewswire/ -- The St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants, is proud to introduce its 2024 Ambassadors who along with their families, will share their unique journey and experiences associated with childhood cancer.

Key Points: 
  • The St. Baldrick's Foundation introduces its 2024 Ambassadors to raise awareness about the need to fund childhood cancer research to find cures and better treatments.
  • LOS ANGELES, Jan. 3, 2024 /PRNewswire/ -- The St. Baldrick's Foundation , the largest charity funder of childhood cancer research grants , is proud to introduce its 2024 Ambassadors who along with their families, will share their unique journey and experiences associated with childhood cancer.
  • Now 12 years in remission, Scott is enjoying the 9th grade and is a passionate advocate for childhood cancer research.
  • Continue following the St. Baldrick's 2024 Ambassadors' heroic stories on the St. Baldrick's blog and social media channels: Facebook , X , Instagram , YouTube , Tik Tok and LinkedIn .

SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones

Retrieved on: 
Wednesday, January 3, 2024
Mesothelioma, Therapeutic index, Doctor of Science, Food, Survival, Lymphoma, Bone marrow, BLA, Ovarian cancer, GPS, MRD, FDA, Type, CMC, CR2, MD, Nivolumab, WT1, Clinical trial, SLS, Acute myeloid leukemia, Patient, Safety, PTCL, AML, Pembrolizumab, Pharmaceutical industry

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and will host a corporate webinar at 8:30 am ET.

Key Points: 
  • “2023 was a very productive year for SELLAS,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS.
  • Dr. Stergiou continued: “We hope to build on this excellent progress and look forward to multiple clinical milestones that have the potential to create significant value for our shareholders.
  • Meaningful cell killing activity, defined as ≥50% reduction in blasts in the bone marrow, was observed at several dose levels.
  • This study is fully funded by the Company’s partner for SLS009, GenFleet Therapeutics (Shanghai), Inc. and is being conducted in China.

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Retrieved on: 
Wednesday, January 3, 2024
APLM, Survival, Medicine, Prognosis, Greater, Disease, Incidence, Peking Union Medical College, Cancer, Acute myeloid leukemia, Patient, AML

This Phase 3 bridging study is being performed in China with Chinese r/r AML patients.

Key Points: 
  • This Phase 3 bridging study is being performed in China with Chinese r/r AML patients.
  • Apollomics licensed uproleselan from GlycoMimetics (Nasdaq: GLYC), including the rights to clinical development, production and commercial sales in the Greater China market (Mainland China, Hong Kong, Macau and Taiwan).
  • “AML is a highly aggressive hematological cancer, and the prognosis of patients with relapsed or refractory disease is extremely poor.
  • AML remains a major unmet medical need in China with an incidence of close to 40,000 patients every year.

President Joe Biden and First Lady Jill Biden brighten spirits at Children’s National Hospital

Retrieved on: 
Saturday, December 23, 2023
First, Holiday, MHA, Entrance Hall, Nursing, Bess Truman, Christmas, Patient, Acute myeloid leukemia, First lady

WASHINGTON, D.C., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Today, President Joe Biden and First Lady Jill Biden spread holiday cheer to patients, families and staff at Children’s National Hospital.

Key Points: 
  • WASHINGTON, D.C., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Today, President Joe Biden and First Lady Jill Biden spread holiday cheer to patients, families and staff at Children’s National Hospital.
  • The First Lady visits are an annual hospital tradition that dates back more than 75 years to Bess Truman, who stopped by to see families who couldn’t spend their holidays at home.
  • This is the third time President Biden joined the First Lady for the visit.
  • “We’re grateful to the President and First Lady for continuing this longstanding holiday tradition.”
    The President and First Lady were escorted by 10-year-old Samukh Arunkumar.

Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Retrieved on: 
Friday, December 22, 2023
Gene, Research and development, SNTI, Food, IND, NOT, FDA, SAN, Doctor of Philosophy, Clinical trial, Cancer, FLT3, Patient, Acute myeloid leukemia, Safety, CD33, Development, AML, Synthetic biology, IL15

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies while sparing healthy bone marrow cells.

Key Points: 
  • The dose finding trial will evaluate two dose levels, either 1 or 1.5 billion SENTI-202 cells, administered after lymphodepleting conditioning in adult patients with relapsed or refractory (r/r) CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia (AML).
  • “Clearance of our IND application for SENTI-202 is a tremendous milestone and marks an important achievement for Senti as we transition to a clinical-stage therapeutics company,” said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio.
  • Senti Bio believes this approach can lead to more effective and durable responses in patients.
  • Through Senti Bio’s previously announced agreement with GeneFab, the Company has prepaid the majority of manufacturing-related expenses through the completion of the Phase 1 trial.

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Retrieved on: 
Thursday, December 21, 2023
Marketing, Doctor of Science, Food, FDA, CDK9, HDAC, ODD, MD, Therapy, SLS, Belinostat, Patient, Acute myeloid leukemia, Safety, Diagnosis, PTCL, Lymphoma, Bone marrow, Pharmaceutical industry

NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SLS009, the Company’s novel and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory (r/r) Peripheral T-cell Lymphomas (PTCL).

Key Points: 
  • “We are delighted to announce the FDA’s granting of ODD for SLS009, marking another significant milestone following the recent Fast Track Designation by the FDA for PTCL,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS.
  • “In the recently completed dose-escalation portion of the Phase 1 trial in r/r hematological malignancies, SLS009 achieved clinical responses in PTCL including two patients reaching complete response.
  • The patients who achieved complete response in the SLS009 study were previously treated with regimens containing an HDAC inhibitor.
  • These benefits include assistance in the drug development process, tax credits for qualified clinical costs, exemptions from certain FDA fees and seven years of marketing exclusivity.

Treadwell Therapeutics Announces a Presentation at the 2023 ASH Annual Meeting and Advisory Board Meeting

Retrieved on: 
Friday, December 15, 2023
Cellular, Transplant, Division, TP53, Disease, MD Anderson Cancer Center, MD, SAN, Society, Therapy, Cancer, Acute myeloid leukemia, PD, ASH, Poster, Chronic myelomonocytic leukemia, University, AML, Myelodysplastic syndrome, PLK4, Pharmaceutical industry

TORONTO and SAN MATEO, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel first-in-class medicines for unmet needs in cancer, today announced a presentation for the Company's lead program, CFI-400945, a first-in-class inhibitor of Polo-like Kinase 4 (PLK4) being advanced in relapsed/refractory AML, at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held from December 9-12, 2023. Treadwell also conducted a clinical advisory board meeting on December 10th at ASH with experienced experts in the treatment of AML and in clinical trials of novel agents, which included current investigators and thought leaders new to the program.

Key Points: 
  • Treadwell also conducted a clinical advisory board meeting on December 10th at ASH with experienced experts in the treatment of AML and in clinical trials of novel agents, which included current investigators and thought leaders new to the program.
  • "CFI-400945 is demonstrating complete remissions as a single agent and in combination with azacitadine in relapsed, adverse risk AML, including those with TP53 mutant disease.
  • Three of 6 evaluable patients with AML achieved a response (MLFS=2, CRi=1 with MRD+) at the 96mg dose​.
  • PK characteristics support daily dosing of CFI-400945 and PD studies are ongoing​.